Smoking cessation is one of the few telehealth categories where the clinical evidence, the public-health incentive and the commercial demand all point the same way. It is also one of the easiest to launch badly — a landing page that ships pharmacotherapy with no behavioural support and no prescriber judgement. This is the operator's map: the treatment options, what the prescriber has to assess, and where the regulation actually bites.
Where smoking cessation telehealth fits in the UK market
Roughly one in eight UK adults still smokes, and the government's ambition of a smokefree England keeps stop-smoking firmly on the policy agenda. Most quit attempts are unsupported and fail; the ones supported by a combination of medication and behavioural help succeed far more often. That gap — between how people try to quit and what actually works — is the opening for a telehealth service.
The commercial model is usually subscription or course-based: an assessment, a treatment plan, medication supplied through a registered pharmacy, and structured support over the following weeks. It sits naturally alongside adjacent verticals a brand may already run, and the clinical risk profile is lower than controlled-drug categories — which makes it a sensible early vertical for a new operator.
The treatment map: NRT, varenicline, bupropion, and cytisine
Nicotine replacement therapy (NRT) — patches, gum, lozenges, inhalators, and mouth or nasal spray — is the backbone. Most NRT is available as a pharmacy (P) or general-sale product, so much of it can be supplied without a prescription, and combination NRT (a patch plus a fast-acting form) is well evidenced. Prescription-only oral options sit on top of that.
The main prescription treatments are:
- Varenicline — a prescription-only oral treatment. UK supply was interrupted in 2021 over a manufacturing impurity, and generic varenicline has since returned to the market; confirm current availability with your dispensing partner.
- Bupropion — a prescription-only oral option, contraindicated where there is a history of seizures or an eating disorder.
- Cytisine — recommended by NICE as a treatment option; availability has been variable, so plan supply carefully.
- NRT on prescription — useful where a patient wants it supplied and supported as part of a plan rather than bought over the counter.
What the prescriber actually has to assess
The prescriber's job is not to rubber-stamp a request. Before an oral treatment, they need to work through contraindications and cautions: mental-health history, pregnancy or breastfeeding, seizure history for bupropion, renal function, current medicines and interactions, and previous quit attempts. Varenicline historically carried neuropsychiatric warnings; while later evidence was largely reassuring and product information was updated, a mental-health history still needs active consideration and follow-up.
This is exactly the kind of higher-touch prescribing the GPhC expects to be led by clinical judgement, not an unmonitored questionnaire. A safe service builds those checks into the consultation and documents the reasoning — not just the outcome.
Regulatory frame: GPhC, NICE NG209, and MHRA
Three reference points matter. The GPhC's guidance for pharmacies providing services at a distance sets the expectations for identity verification, appropriateness and safeguards. NICE NG209 (tobacco: preventing uptake, promoting quitting and treating dependence) is the clinical anchor — its core message is to offer behavioural support and pharmacotherapy together, because the combination outperforms either alone. And MHRA rules govern how you advertise: claims must be accurate and you cannot promote prescription-only medicines to the public.
One practical trap is vaping. Nicotine vapes are not licensed medicines, and while national schemes encourage switching, marketing them as a medical treatment invites regulatory attention. Keep the medical service and any vape offer clearly separated. For the advertising rules in detail, see our guide to UK telehealth marketing under MHRA and ASA.
Smoking cessation is a low-controlled-drug, high-evidence vertical — but the evidence is for medication plus behavioural support. A service that ships pharmacotherapy with no support is not just weaker clinically; it is easier for a regulator to characterise as supply rather than care.
Behavioural support is the part operators skip
The evidence is blunt: medication plus behavioural support beats medication alone. Yet the behavioural half is the part most consumer services quietly drop, because it costs staff time and does not sell as neatly as a pill. Skipping it produces worse quit rates, more churn, and a service that looks like supply dressed up as care.
Support does not have to be expensive to be real: structured check-ins at the moments relapse is most likely, a clear plan for a quit date, and someone to adjust treatment when the first attempt stalls. Build it into the subscription rather than bolting it on, and design the operating procedures around it — our guide to writing clinical SOPs covers how to make that repeatable.
Building the operational stack
The operational spine is the same as any prescribing vertical: identity verification, a prescriber workflow with proper record-keeping, a registered dispensing pharmacy, fulfilment, and a support function that can handle clinical questions. Smoking cessation adds a support cadence — the follow-up schedule — that has to be built and staffed, not improvised.
Whether you build that stack or partner for it is the first real decision. The regulated layer (pharmacy, prescriber governance, dispensing) is slow and expensive to build from scratch; the brand, the support experience and the funnel are where a new entrant actually differentiates. Our launch checklist walks the sequence end to end.
Most quit attempts are unsupported and fail. The commercial opportunity in smoking cessation is not the medicine — it is being the service that actually supports the attempt.
How PExpo supports a smoking cessation launch
PExpo provides the regulated layer — registered dispensing, prescriber governance, pharmacovigilance and the patient record — so a brand can launch a smoking cessation service without building a pharmacy. You bring the brand, the funnel and the support experience; the compliant core is already in place.
That split lets a new vertical go live in weeks rather than quarters, with the higher-risk elements handled by an operator that already runs them. See our brand model for the operational scope, or our pricing for how the commercials work.
Smoking cessation rewards operators who treat it as a supported clinical programme rather than a supply funnel. Get the prescriber governance, the treatment map and the behavioural support right, and it is one of the more defensible verticals a UK telehealth brand can launch. See our launch checklist and brand model for the operational detail.
Frequently asked questions
Do you need a prescription for a stop-smoking service in the UK?
Not for most NRT, which is available as a pharmacy or general-sale product. Oral treatments such as varenicline and bupropion are prescription-only and need a prescriber's assessment. A telehealth service typically combines both under prescriber oversight and a registered pharmacy.
Is varenicline available again in the UK?
UK supply was interrupted in 2021 over a manufacturing impurity, and generic varenicline has since returned to the market. Availability can still vary, so confirm current stock with your dispensing partner before promoting it.
What behavioural support does a compliant service need?
NICE NG209 recommends behavioural support alongside medication because the combination is more effective. In practice that means a quit-date plan, structured follow-ups at high-relapse moments, and the ability to adjust treatment when an attempt stalls.
